Phase I laboratory of Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
NCT Number: NCT02291471
The purpose of this study to assess the MTD and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers.
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
Beijing, Beijing Municipality, 100044, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 3 weeks
Time frame: 3 weeks
Time frame: Pre-dose,2、4、12、24、36、48、60、72、84、96、120、144、168、216、264、312、384 and 480hours after the start of subcutaneous injection
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Industry
An Open, Dose Escalation, Single Dose Study to Assess Tolerance and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02694185
Behavior, Cardiovascular Diseases
San Francisco, California, United States
View Trial DetailsNCT07512401
Connective Tissue Diseases, Musculoskeletal Diseases
View Trial DetailsNCT07138157
Arthritis, Arthritis, Juvenile
Istanbul, Türkiye, Turkey (Türkiye)
View Trial DetailsNCT07436494
Anxiety, Anxiety Disorders
Bursa, Türkiye, Turkey (Türkiye)
View Trial Details